专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明授权

KR101040396B1 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법 失效
标题翻译：修饰的人血小板生成素多肽片段及其生产方法
公开(公告)号：KR101040396B1
公开(公告)日：2011-06-09
申请号：KR1020100005348
申请日：2010-01-20
申请人： 한올바이오파마주식회사
发明人： 김성욱 , 전성수 , 박승국 , 정재갑 , 이성률 , 송연정 , 심원조
IPC分类号： C07K14/505 , C12N15/12 , C12N15/63 , A61K38/17
CPC分类号： C07K14/515 , A61K38/196 , Y02A50/473
摘要： 본 발명은 생체내외 (in vivo, in vitro)에서 혈소판 증식능을 가지면서 생체내에 존재하는 단백질 분해효소 (protease)에 대한 저항성이 향상된 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 (human thrombopoietin polypeptide fragment)을 제공한다.
摘要翻译：本发明涉及一种经修饰的人血小板生成素多肽片段，其在体内和体外具有改善的血小板生长潜力，并且对存在于活体内的蛋白酶具有改善的抗性，提供。

72. 发明公开

KR1020110053837A Ｎ1-(펜에틸)-Ｎ2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 失效
标题翻译： N1-（苯乙烯）-N取代的双胍衍生物，其制备方法和包含该化合物的药物组合物
公开(公告)号：KR1020110053837A
公开(公告)日：2011-05-24
申请号：KR1020090110521
申请日：2009-11-16
申请人： 한올바이오파마주식회사 , 한국화학연구원
发明人： 김성욱 , 전성수 , 오병규 , 강민석 , 천혜경 , 김광록 , 이상달 , 정원훈 , 이종철
IPC分类号： C07C279/26 , C07C277/04 , A61K31/155 , A61P3/10
摘要： PURPOSE: An N1-(phenethyl)-N2-substituted biguanide derivative is provided to ensure excellent blood glucose drop action and lipid lowering action even with a little dosage compared existing drug and to enable use for the treatment of diabetes, obesity, hyperlipidemia, hypercholesterolemia, steatosis, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer etc. CONSTITUTION: A compound or pharmaceutically acceptable salts are represented by chemical formula 1. In chemical formula 1, R is C1-12 alkyl, C1-12 alkenyl or C1-12 alkynyl substituted or unsubstituted with one or more substituents selected from C3-8 cycloalkyl and C5-12 aryl; C3-8 cycloalkyl substituted or unsubstituted with one or more substituents selected from halogen, hydroxyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy and C5-12 aryl; and C5-12 aryl substituted or unsubstituted with one or more substituents selected from halogen, hydroxyl, C1-6 alkyl, C1-6 alkenyl, C1-6 alkynyl, C1-6 alkoxy and C3-8 cycloalkyl.
摘要翻译：目的：提供N1-（苯乙基）-N2-取代双胍衍生物，以确保优异的血糖降低作用和降脂作用，即使与现有药物相比，用量少，可用于治疗糖尿病，肥胖，高脂血症，高胆固醇血症，脂肪变性，冠状动脉疾病，骨质疏松症，多囊卵巢综合征，代谢综合征，癌症等。构成：化学式1表示化合物或其药学上可接受的盐。在化学式1中，R是C 1-12烷基，C 1-12链烯基或被一个或多个选自C 3-8环烷基和C 5--12芳基的取代基取代或未取代的C1-12炔基; 羟基，C 1-6烷基，C 1-6烯基，C 1-6炔基，C 1-6烷氧基和C 5-12芳基的取代或未取代的C 3-8环烷基; 和被选自卤素，羟基，C 1-6烷基，C 1-6烯基，C 1-6炔基，C 1-6烷氧基和C 3-8环烷基的一个或多个取代基取代或未取代的C 5-12芳基。

73. 发明公开

KR1020100085879A 변형된 인간 트롬보포이에틴 폴리펩타이드 절편 및 그의 제조방법 失效
标题翻译：改性人类血小板聚糖片段及其制备方法
公开(公告)号：KR1020100085879A
公开(公告)日：2010-07-29
申请号：KR1020100005348
申请日：2010-01-20
申请人： 한올바이오파마주식회사
发明人： 김성욱 , 전성수 , 박승국 , 정재갑 , 이성률 , 송연정 , 심원조
IPC分类号： C07K14/505 , C12N15/12 , C12N15/63 , A61K38/17
CPC分类号： C07K14/515 , A61K38/196 , Y02A50/473
摘要： PURPOSE: A mutated human thrombopoietin polypeptide fragment is provided to ensure platelet proliferation ability in vivo and in vitro and improved resistance to protease in vivo. CONSTITUTION: A human thrombopoietin polypeptide fragment contains mutated or substituted amino acid at 3rd, 6th, 8-12th, 14-18th, 20-23th, 25th, 26th, 31-34th, 39-41th, 43-46th, 48-52th, 55-57th, 56th, 60th, 62th, 64-67th, 69-79th, 81th, 86th, 89-91th, 93th, 95th, 97-104th, 107-109th, 112th, 116th, 117th, 120-123th, 126th, 128th, 129th, 131th, 133-147th, 150th, or 152th amino acid. A pharmaceutical formulation contains mutated TPO fragment having the mutated amino acid. A pharmaceutical composition for preventing or treating thrombocytopenia or diseases caused by thrombocytopenia contains the mutated TPO fragment.
摘要翻译：目的：提供突变的人血小板生成素多肽片段，以确保体内和体外的血小板增殖能力，并提高体内对蛋白酶的抗性。构成：人血小板生成素多肽片段在第3,6,6,8,12,14,18,20-23,25,26,31-34,49-41,43-46,48-52，含有突变或取代的氨基酸，第55-57号，第56号，第六十六次，第六十六次，第六十六次，第六十六次，第六次，第六次，第六次，第六次，第六十六次，第六十七次，第六十六次，第128位，第129位，第131位，第133-147位，第150位或第152位氨基酸。药物制剂含有具有突变的氨基酸的突变的TPO片段。用于预防或治疗由血小板减少症引起的血小板减少症或疾病的药物组合物含有突变的TPO片段。

74. 发明公开

KR1020100041189A 메트포르민의 경구투여용 서방성 제제 및 이의 제조방법 有权
标题翻译：控制释放配方用于口服和口服药物的方法
公开(公告)号：KR1020100041189A
公开(公告)日：2010-04-22
申请号：KR1020080100245
申请日：2008-10-13
申请人： 한올바이오파마주식회사
发明人： 김성욱 , 전성수 , 구자성 , 장석영
IPC分类号： A61K9/22 , A61K31/155
CPC分类号： A61K9/2054 , A61K9/0053 , A61K9/2031 , A61K31/155 , A61K47/34 , A61K47/38 , Y10S514/866
摘要： PURPOSE: A sustained release formulation for oral administration of metformin and a method for manufacturing the same are provided to control release rate of metformin and maintain uniform concentration of the matformin in blood. CONSTITUTION: A sustained release formulation for oral administration of metformin contains a metformin as an active ingredient or its pharmaceutically acceptable salt, 2-9 weight parts of hydrophobic polyvinyl acetate or ethylcellulose as a sustained release carrier, and 10-30 weight parts of polyethyleneoxide as a swelling polymer. The sustained release formulation additionally contains pharmaceutically acceptable additive of diluents, binder, disintegrating agent, or lubricating agent.
摘要翻译：目的：提供口服二甲双胍的缓释制剂及其制备方法，以控制二甲双胍的释放速率，并维持血液中的马立比斯浓度均匀。构成：口服二甲双胍的持续释放制剂含有二甲双胍作为活性成分或其药学上可接受的盐，2-9重量份疏水性聚乙酸乙烯酯或乙基纤维素作为缓释载体，和10-30重量份的聚环氧乙烷作为溶胀性聚合物。持续释放制剂另外含有药学上可接受的稀释剂，粘合剂，崩解剂或润滑剂的添加剂。

75. 外观设计

KR3005441250001S 有权
公开(公告)号：KR3005441250001S
公开(公告)日：2009-11-04
申请号：KR3020080044754
申请日：2008-10-17
申请人： 한올바이오파마주식회사
设计人： 김성욱 , 전성수 , 이문재

76. 外观设计

KR3005441250000S 有权
公开(公告)号：KR3005441250000S
公开(公告)日：2009-11-03
申请号：KR3020080044661
申请日：2008-10-17
申请人： 한올바이오파마주식회사
设计人： 김성욱 , 전성수 , 이문재

77. 发明公开

KR1020090114328A 약제학적 제제 有权
标题翻译：药物制剂
公开(公告)号：KR1020090114328A
公开(公告)日：2009-11-03
申请号：KR1020090037380
申请日：2009-04-29
申请人： 한올바이오파마주식회사
发明人： 김성욱 , 전성수 , 이아람 , 최진원
IPC分类号： A61K9/22 , A61K9/52 , A61K47/38 , A61P9/12
CPC分类号： A61K45/06
摘要： PURPOSE: A pharmaceutical formulation containing atorvastatin and irbesartan is provided to effectively prevent and treat hypertension, hyperlipidemia and their complication. CONSTITUTION: A pharmaceutical formulation of which release is controlled comprises a immediate release compartment containing atorvastatin as a pharmacologically active ingredient, its pharmaceutically acceptable salt, or its isomer, and a sustained release compartment containing irbesartan as pharmacologically active ingredient, its pharmaceutically acceptable salt or its isomer. The sustained release compartment contains osmosis controlling agent and is coated with semi-permeable coating substrate. The pharmaceutical formulation is used in the form of matrix.
摘要翻译：目的：提供含阿托伐他汀和厄贝沙坦的药物制剂，以有效预防和治疗高血压，高脂血症及其并发症。构成：释放被控制的药物制剂包括含有阿托伐他汀作为药理学活性成分的立即释放隔室，其药学上可接受的盐或其异构体，以及含有厄贝沙坦作为药理学活性成分的缓释隔室，其药学上可接受的盐或其异构体。持续释放隔间含有渗透控制剂，并涂有半透性涂层基材。药物制剂以基质的形式使用。

78. 发明公开

KR1020090114321A 심혈관계 질환 치료용 약제학적 제제 无效
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：KR1020090114321A
公开(公告)日：2009-11-03
申请号：KR1020090037373
申请日：2009-04-29
申请人： 한올바이오파마주식회사
发明人： 김성욱 , 전성수 , 구자성 , 김진욱 , 남태영
IPC分类号： A61K9/22 , A61K9/28 , A61P9/12 , A61K47/38
CPC分类号： A61K45/06
摘要： PURPOSE: A pharmaceutical formulation containing simvastatin and valsartan as pharmacologically active ingredient is provided to enhance drug efficiency with reduced side effects. CONSTITUTION: A pharmaceutical formulation contains an immediate release compartment containing simvastatin as a pharmacologically active ingredient, its isomer or its pharmaceutically acceptable salt and a sustained release compartment containing valsartan as a pharmacologically active ingredient, its isomer or its pharmaceutically acceptable salt. The valsartan is released two hour after releasing of simvastatin. The pharmaceutical formulation is used in the form of particle, granule, pellet, tablet of sustained release compartment and capsule containing particle, granule, pellet, or tablet of immediate release compartment.
摘要翻译：目的：提供含有辛伐他汀和缬沙坦作为药理活性成分的药物制剂，以提高药物效率，减少副作用。构成：药物制剂包含含有辛伐他汀作为药理活性成分，其异构体或其药学上可接受的盐的缓释隔室和含有缬沙坦作为药理学活性成分，其异构体或其药学上可接受的盐的缓释隔室。释放辛伐他汀后两小时释放缬沙坦。药物制剂以颗粒，颗粒，丸剂，持续释放隔间的片剂和含有颗粒，颗粒，丸剂或立即释放隔间的片剂的形式使用。

79. 发明公开

KR1020090114122A 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와치아자이드계 화합물을 포함하는 약학적 조성물 无效
标题翻译：含有血管紧张素Ⅱ受体阻断剂和噻唑的控释药物组合物
公开(公告)号：KR1020090114122A
公开(公告)日：2009-11-03
申请号：KR1020080039909
申请日：2008-04-29
申请人： 한올바이오파마주식회사
发明人： 김성욱 , 전성수 , 조영관 , 구자성 , 이아람 , 손재운
IPC分类号： A61K9/22 , A61K31/495
CPC分类号： A61K9/2077 , A61K9/209 , A61K9/28 , A61K9/4808 , A61K31/4178 , A61K31/635 , A61K47/26 , A61K47/32 , A61K47/36 , A61K47/38
摘要： PURPOSE: A pharmaceutical composition containing angiotensin-II-receptor blocker and thiazides compound is provided to administer the complex formulation and maximize prevention effect of drugs with less side effect. CONSTITUTION: A complex composition having controlled release contains controlled release compartment with thiazides compound and immediate release compartment with angiotensin-II-receptor blocker as an active ingredient. The angiotensin-II-receptor blockers rosartan, valsartan, irbesartan, candesartan, telmisartan, their isomer or pharmaceutically acceptable salt.
摘要翻译：目的：提供含有血管紧张素II受体阻断剂和噻嗪类化合物的药物组合物，用于给予复合制剂，并最大限度地发挥副作用少的药物的预防作用。构成：具有控制释放的复合组合物含有具有噻嗪类化合物和具有血管紧张素-II受体阻断剂作为活性成分的立即释放隔室的控释室。血管紧张素II受体阻断剂罗沙坦，缬沙坦，厄贝沙坦，坎地沙坦，替米沙坦，其异构体或药学上可接受的盐。

80. 发明授权

KR100888131B1 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 失效
标题翻译：通过Chronotherapy理论进行心血管疾病治疗的联合准备。
公开(公告)号：KR100888131B1
公开(公告)日：2009-03-11
申请号：KR1020070101492
申请日：2007-10-09
申请人： 한올바이오파마주식회사
发明人： 김성욱 , 전성수 , 조영관 , 구자성 , 선상욱
IPC分类号： A61K9/22 , A61K31/00 , A61P9/00
CPC分类号： A61K31/4184 , A61K9/2077 , A61K9/2081 , A61K9/2086 , A61K9/209 , A61K9/2853 , A61K9/2866 , A61K9/5084 , A61K31/4178 , A61K31/4422 , A61K45/06 , A61K2300/00
摘要： 본 발명은 암로디핀과 같은 디하이드로피리딘계 칼슘채널차단제와 로사르탄과 같은 ARB(Angiotensin-2 수용체 길항제)의 복합제제에 관한 것이다. 더욱 상세하게 설명하면 두성분간의 시간 차 용출을 가능케 함으로서 약물 대사 효소 상호 작용 이론과 시간차 투약 원리에 적합하도록 제제화하여 이 두 성분을 단일제로 따로 따로 동시에 복용하는 경우보다 약효를 증가시키고 부작용을 감소시킬 수 있을 뿐 아니라 심혈관계 질환합병증 발생 위험도가 가장 높은 일중 시간대에 그 약효를 최대한 유지할 수 있도록 한 심혈관계 질환 치료 및 예방용 기능성 시간차 복합제제에 관한 것이다.
시간차 투약 원리, 암로디핀, 디하이드로피리딘계 칼슘채널차단제, 로사르탄, ARB(Angiotensin-2 수용체 길항제), 항압 효과

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式